drugset / Trial / NCT01262911

Effect of SRT2379 on Endotoxin-Induced Inflammation

NCT01262911 ↗

Phase 1 Completed 17 enrolled Sirtris, a GSK Company GlaxoSmithKline · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice. The objective of this study is to test if SRT2379 may be a novel compound for the treatment of inflammatory disorders in man.

Timeline

Start
2011-02-17
Primary completion
2011-04-26
Completion
2011-04-26

Drugs

EvaluationDrugModalityDoseRoute
Comparator SRT2379 Small molecule 1 g Oral